About us

At Future Live, we believe in an approach that integrates scientific research with a genuine focus on people’s well-being.
Since 2012, we have been dedicated to the development of nutraceutical supplements and innovative health solutions, with a constant commitment to quality, efficacy, and safety.
Today, thanks to the trust of physicians and patients, we are a recognized reference in the urological, gynecological, and nephrological fields, supported by an increasingly solid medical information network and a growing presence in the digital sector.
Our goal is simple yet ambitious: to improve people’s quality of life, every day.

For over ten years, Future Live has been operating with an approach grounded in scientific rigor and innovation.
Our philosophy combines the reliability of traditional ingredients with the development of modern formulations, in order to deliver high-quality, trustworthy products aligned with the latest evidence in the nutraceutical field.

OUR HISTORY

Since its foundation, Future Live has turned its expertise into a path of continuous growth.
Each milestone achieved represents a step forward in our commitment to delivering effective solutions aligned with today’s needs.

2012

Foundation of Future Live

2013

Acquisition of the Cal-Car and Cal-Ace brands

2014

Launch of Solvhoren Retard

2015

Launch of 5AlfaProst

2016

Launch of Enzuryl Cist

Launch of Solvhoren Bustine

First clinical study on FeRNApyd (acute setting)

2017

Launch of Enflog 360

Launch of FeRNApyd

2018

Launch of Decand

2019

Launch of Pealgyl

2022

Launch of Enflog Gel Vaginale

Start of the second clinical study on FeRNApyd

2023

Completion of the second clinical study on FeRNApyd

Filing of Future Live’s first patent

2024

Launch of Enzuryl D-Mannosio

2025

Granting of Future Live’s first patent

2026

Publication of the second clinical study on FeRNApyd

Launch of a new product